In COVID-19 clinical update #67, Daniel Griffin reviews antibodies to the virus early in the US, serology testing of blood donations, MIS-C in children under 21, myocarditis in competitive athletes, ER visits for suspected suicide attempts, delta variant in Scotland, Novavax vaccine phase 3 results, vaccine coverage in pregnant women, early monoclonal administration reduces hospitalization and mortality, casirivimab and imdevimab recovery trial results, and CDC guidance on postacute sequelae.
TWiV describes how human behavior, not increased transmissibility, led to increased spread of a SARS-CoV-2 variant throughout Europe in summer 2020, and nanobodies from camelid mice and llamas that efficiently neutralize variants of concern.
In COVID-19 clinical update #66, Daniel Griffin covers treatment guidelines from IDSA, hospitalization of adolescents, estimating epidemiological dynamics from viral load distributions, incidence of infection according to baseline antibody status, assessment of reinfection in Italy, need for vaccination in previously infected individuals, assessment of protection against reinfection, antimicrobial use in hospitalized patients, effect of single dose ivermectin, and a trial of aspirin in hospitalized patients.
David joins TWiV to relate how his near-death experience with Castleman’s disease motivated him to found the Center for Cytokine Storm Treatment & Laboratory and the CORONA project to identify and track all treatments reported for COVID-19 in an open-source data repository.
TWiV reviews the new nomenclature for SARS-CoV-2 variants, effectiveness of Pfizer/BioNTech vaccine against variants, modified Moderna vaccine against variants, impact of COVID-19 interventions on influenza in China and the US, and binding of RaTG13 spike protein to ACE2 of multiple species.
In COVID-19 clinical update #65, Daniel Griffin summarizes effects of non-pharmaceutical interventions, updated summer camp guidance from CDC, serology testing not recommended by FDA, antigen tests during a music event, inhibition of vaccine immunogenicity by methotrexate, phase 3 trial results for colchicine, and small airway disease as a post-acute sequelae.
In COVID-19 clinical update #64, Daniel Griffin covers new guidance from NY on day camps, mitigation and infection rates in schools, testing to sustain in person instruction, Moderna mRNA vaccine highly effective in adolescents, longer storage of Pfizer vaccine, FDA EUA for sotrovimab, and persistent illness in UK children.
In COVID-19 clinical update #63, Daniel Griffin reviews cases at child care facilities, estimates of mRNA vaccine effectiveness, risk of reinfection in university students, enhanced antibody generation with extended interval of mRNA vaccination, no benefit of convalescent plasma in hospitalized patients, and risk of clinical sequelae after acute infection.
In COVID-19 clinical update #61, Daniel Griffin reviews a modeling of future hospitalizations and deaths by vaccination rates and non pharmaceutical intervention scenarios, performance evaluation of rapid antigen tests, children making up a growing share of new cases, antibody response to mRNA vaccine in solid organ transplant recipients, and outcomes in hospitalized patients treated with tocilizumab.
In COVID-19 clinical update #60, Daniel Griffin summarizes CDC guidance for summer camps, how to protect yourself when fully vaccinated, updated recommendation for J&J vaccine, declining global case fatality rate, and characterization of post-acute sequelae.